Rationale for anticoagulant therapy of pulmonary fibrosis
- PMID: 24484337
- PMCID: PMC3977727
- DOI: 10.1164/rccm.201305-0845LE
Rationale for anticoagulant therapy of pulmonary fibrosis
Comment in
-
Reply: rationale for anticoagulant therapy of pulmonary fibrosis.Am J Respir Crit Care Med. 2014 Feb 1;189(3):363. doi: 10.1164/rccm.201307-1328LE. Am J Respir Crit Care Med. 2014. PMID: 24484338 Free PMC article. No abstract available.
Comment on
-
A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.Am J Respir Crit Care Med. 2012 Jul 1;186(1):88-95. doi: 10.1164/rccm.201202-0314OC. Epub 2012 May 3. Am J Respir Crit Care Med. 2012. PMID: 22561965 Free PMC article. Clinical Trial.
References
-
- Ohba T, McDonald JK, Silver RM, Strange C, LeRoy EC, Ludwicka A. Scleroderma BAL fluid contains thrombin, a mediator of human lung fibroblast proliferation via induction of the PDGF-alpha receptor. Am J Respir Cell Mol Biol. 1994;10:405–412. - PubMed
-
- Hernández-Rodríguez NA, Cambrey AD, Harrison NK, Chambers RC, Gray AJ, Southcott AM, duBois RM, Black CM, Scully MF, McAnulty RJ, et al. Role of thrombin in pulmonary fibrosis. Lancet. 1995;346:1071–1073. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
